Table 1.

Inhibition of KCI-18 Cell Growth by Sunitinib Combined with Gemcitabine In Vitro.

Treatment	Survival Fraction (Mean ± SD)	% Inhibition
Control	1.00	0
Gemcitabine (1 nM)	0.52 ± 0.04*	48
Gemcitabine (2.5 nM)	0.21 ± 0.01*	79
Sunitinib (1 µM)	0.64 ± 0.02*	36
Gemcitabine (1 nM) + Sutent (1 nM)	0.19 ± 0.01†	81
Gemcitabine (2.5 nM) + Sutent (2.5 µM)	0.07 ± 0.02†	93

KCI-18 cells were treated with gemcitabine at 1 and 2.5 nM or sunitinib at 1 µM or both drugs in combination for 24 hours, and then cells were plated in a colony formation assay for 10 days. The mean survival fraction was calculated from triplicate wells.

^*P < .001.

^†P < .0001.